Uppsala University Hospital
regionuppsala.seLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
70
Active
17
Phase 3
0
Total enrollment
610,565
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Rituximab | — | — | — | — | — | 1 | |
| the ATMP Protrans | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| Everolimus | — | — | — | — | — | 1 | |
| Cobimetinib | — | — | — | — | — | 1 | |
| Niraparib | — | — | — | — | — | 1 |
Next readouts
- 2024-01-31
- 2028-04-01
- 2028-09
Top conditions
- Atrial Fibrillation3
- Eating Disorders3
- Anorexia Nervosa3
- Sepsis2
- Fecal Incontinence2
- Type 1 Diabetes2
- Obsessive-Compulsive Disorder2
- Anesthesia2
Frequently asked questions about Uppsala University Hospital
- How many clinical trials does Uppsala University Hospital have on ClinicalTrials.gov?
- Uppsala University Hospital is listed as the lead sponsor on 70 clinical trials in ClinicalTrials.gov, 17 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Uppsala University Hospital's trials are in Phase 3?
- 0 of Uppsala University Hospital's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does Uppsala University Hospital focus on?
- Uppsala University Hospital's most-studied conditions on ClinicalTrials.gov are Atrial Fibrillation, Eating Disorders, Anorexia Nervosa, Sepsis, Fecal Incontinence.
- When are Uppsala University Hospital's next clinical trial readouts?
- Uppsala University Hospital has 3 upcoming primary-completion readouts tracked here; the soonest is “A MolEcularly Guided Anti-Cancer Drug Off-Label Trial”, expected around 2024-01-31.